title: The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.
abstract: Early life seizures can result in chronic epilepsy, cognitive deficits and behavioral changes such as autism, and conversely epilepsy is common in autistic children. We hypothesized that during early brain development, seizures could alter regulators of synaptic development and underlie the interaction between epilepsy and autism. The mammalian Target of Rapamycin (mTOR) modulates protein translation and is dysregulated in Tuberous Sclerosis Complex, a disorder characterized by epilepsy and autism. We used a rodent model of acute hypoxia-induced neonatal seizures that results in long term increases in neuronal excitability, seizure susceptibility, and spontaneous seizures, to determine how seizures alter mTOR Complex 1 (mTORC1) signaling. We hypothesized that seizures occurring at a developmental stage coinciding with a critical period of synaptogenesis will activate mTORC1, contributing to epileptic networks and autistic-like behavior in later life. Here we show that in the rat, baseline mTORC1 activation peaks during the first three postnatal weeks, and induction of seizures at postnatal day 10 results in further transient activation of its downstream targets phospho-4E-BP1 (Thr37/46), phospho-p70S6K (Thr389) and phospho-S6 (Ser235/236), as well as rapid induction of activity-dependent upstream signaling molecules, including BDNF, phospho-Akt (Thr308) and phospho-ERK (Thr202/Tyr204). Furthermore, treatment with the mTORC1 inhibitor rapamycin immediately before and after seizures reversed early increases in glutamatergic neurotransmission and seizure susceptibility and attenuated later life epilepsy and autistic-like behavior. Together, these findings suggest that in the developing brain the mTORC1 signaling pathway is involved in epileptogenesis and altered social behavior, and that it may be a target for development of novel therapies that eliminate the progressive effects of neonatal seizures.
authors.affiliation: Department of Neurology, Children's Hospital, Boston, Massachusetts, United States of America.
authors.forename: Delia M
authors.initials: DM
authors.lastname: Talos
authors.forename: Hongyu
authors.initials: H
authors.lastname: Sun
authors.forename: Xiangping
authors.initials: X
authors.lastname: Zhou
authors.forename: Erin C
authors.initials: EC
authors.lastname: Fitzgerald
authors.forename: Michele C
authors.initials: MC
authors.lastname: Jackson
authors.forename: Peter M
authors.initials: PM
authors.lastname: Klein
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Lan
authors.forename: Annelise
authors.initials: A
authors.lastname: Joseph
authors.forename: Frances E
authors.initials: FE
authors.lastname: Jensen
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D015153:Blotting, Western; D004827:Epilepsy / Q000378:metabolism* / Q000503:physiopathology; D007150:Immunohistochemistry; D007608:Kainic Acid / Q000494:pharmacology; D008124:Locomotion / Q000502:physiology; D008297:Male; D051381:Rats; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D058570:TOR Serine-Threonine Kinases; D007608:Kainic Acid